Switch theme
Sign up to access all valuation multiples
XSpray Pharma AB is a pharmaceutical company focused on developing improved PKIs for cancer treatment, leveraging its proprietary HyNap technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Its product portfolio includes Dasynoc and other product candidates in different stages of development such as XS003 nilotinib, XS008 axitinib, and other.
2003
27
Last FY Revenue n/a
LTM EBITDA -$29.9M
$185M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
XSpray Pharma has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$29.9M.
In the most recent fiscal year, XSpray Pharma achieved revenue of n/a and an EBITDA of -$29.1M.
XSpray Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See XSpray Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$29.9M | XXX | -$29.1M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$30.6M | XXX | -$30.0M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$30.5M | XXX | -$30.2M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, XSpray Pharma's stock price is SEK 47 (or $5).
XSpray Pharma has current market cap of SEK 1.8B (or $185M), and EV of SEK 1.8B (or $185M).
See XSpray Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $185M | $185M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, XSpray Pharma has market cap of $185M and EV of $185M.
XSpray Pharma's trades at n/a EV/Revenue multiple, and -6.4x EV/EBITDA.
Equity research analysts estimate XSpray Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
XSpray Pharma has a P/E ratio of -6.1x.
See valuation multiples for XSpray Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $185M | XXX | $185M | XXX | XXX | XXX |
| EV (current) | $185M | XXX | $185M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -6.2x | XXX | -6.4x | XXX | XXX | XXX |
| EV/EBIT | -6.1x | XXX | -6.2x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -6.1x | XXX | -6.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -6.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialXSpray Pharma's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.1M for the same period.
XSpray Pharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
XSpray Pharma's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for XSpray Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 1% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
XSpray Pharma acquired XXX companies to date.
Last acquisition by XSpray Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . XSpray Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was XSpray Pharma founded? | XSpray Pharma was founded in 2003. |
| Where is XSpray Pharma headquartered? | XSpray Pharma is headquartered in Sweden. |
| How many employees does XSpray Pharma have? | As of today, XSpray Pharma has 27 employees. |
| Who is the CEO of XSpray Pharma? | XSpray Pharma's CEO is Mr. Per Andersson. |
| Is XSpray Pharma publicy listed? | Yes, XSpray Pharma is a public company listed on STO. |
| What is the stock symbol of XSpray Pharma? | XSpray Pharma trades under XSPRAY ticker. |
| When did XSpray Pharma go public? | XSpray Pharma went public in 2017. |
| Who are competitors of XSpray Pharma? | Similar companies to XSpray Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of XSpray Pharma? | XSpray Pharma's current market cap is $185M |
| Is XSpray Pharma profitable? | Yes, XSpray Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of XSpray Pharma? | XSpray Pharma's last 12 months EBITDA is -$29.9M. |
| What is the current EV/EBITDA multiple of XSpray Pharma? | Current EBITDA multiple of XSpray Pharma is -6.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
